Key result
Doxorubicin and aclarubicin cause greater cardiomyocyte toxicity than amrubicin, with recovery within ~3 weeks.
Why the study?
Cardiotoxicity is a major cause of drug withdrawal due to poor predictability of animal models, and it remains unclear which cancer patients will develop treatment-limiting heart failure.
Does exposure to different anthracyclines (doxorubicin, aclarubicin, amrubicin) induce distinct molecular and functional cardiotoxic effects in human pluripotent stem cell-derived cardiomyocytes?
Does exposure to different anthracyclines (doxorubicin, aclarubicin, amrubicin) induce distinct molecular and functional cardiotoxic effects in human pluripotent stem cell-derived cardiomyocytes?
This human pluripotent stem cell platform successfully models clinically relevant anthracycline-induced cardiotoxicity and recovery, offering a scalable pre-clinical screening tool for individualized safety assessment.
Answers are grounded in this paper and cite their sources.
May support preferring amrubicin to limit cardiotoxicity; leaves open clinical validation for patient-specific use.
Cardiotoxicity remains a major cause of drug withdrawal, partially due to lacking predictability of animal models. Additionally, risk of cardiotoxicity following treatment of cancer patients is treatment limiting. It is unclear which patients will develop heart failure following therapy. Human pluripotent stem cell (hPSC)-derived cardiomyocytes present an unlimited cell source and may offer individualized solutions to this problem. We developed a platform to predict molecular and functional aspects of cardiotoxicity. Our platform can discriminate between the different cardiotoxic mechanisms of existing and novel anthracyclines Doxorubicin, Aclarubicin, and Amrubicin. Doxorubicin and Aclarubicin unlike Amrubicin substantially affected the transcriptome, mitochondrial membrane integrity, contractile force and transcription factor availability. Cardiomyocytes recovered fully within two or three weeks, corresponding to the intermittent clinical treatment regimen. Our system permits the study of hPSC-cardiomyocyte recovery and the effects of accumulated dose after multiple dosing, allowing individualized cardiotoxicity evaluation, which effects millions of cancer patients treated annually.
No takes yet. Share an insight, caveat, or question.
Schwach et al. (2024) studied Anthracycline-induced cardiotoxicity. Anthracyclines (Doxorubicin, Aclarubicin, Amrubicin) vs. DMSO control was evaluated on Cardiotoxicity assessed by functional impairment (contractile force, calcium kinetics), molecular damage, and cell viability. Doxorubicin and aclarubicin substantially impaired the transcriptome, mitochondrial membrane integrity, and contractile force of hPSC-cardiomyocytes compared to amrubicin, with full recovery observed within 2-3 weeks at intermittent sub-lethal doses.
Synapse has enriched 10 related papers. Consider them for comparative context: